Navigation Links
Corgenix Reports Third Quarter Fiscal 2009 Financial Results
Date:5/14/2009

's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

                          SUMMARY OF FINANCIAL HIGHLIGHTS
      ($000 of U.S. dollars except shares outstanding and per share amounts)

                   CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
                                 OPERATIONAL DATA

                       Three Months Ended           Nine Months Ended

                      March 31,   March 31,      March 31,      March 31,
                        2009        2008           2009           2008
                     (unaudited) (unaudited)    (unaudited)    (unaudited)

    Net sales          $2,032      $1,951         $6,029         $6,455
    Gross profit        1,144       1,140          3,404          3,627
    Total operating
     expenses           1,205       1,203          3,616          3,464
    Operating income
     (loss)               (61)        (63)          (211)           163
    Net loss             (454)       (352)        (1,064)        (1,101)
    Weighted average
     shares
     outstanding   30,286,922  26,452,150     30,219,233     23,601,550
    Net loss per
     share             $(0.02)     $(0.01)        $(0.04)        $(0.05)
    Adjusted EBITDA      $267        $123           $456           $652



                            SUMMARY BALANCE SHEET DATA
                                  (in thousands)

                                      March 31, 2009   June 30, 2008
                                       (unaudited)       (audited)

    Cash                                   $665            $1,520
    Working capital                       2,150             2,889
    Total assets                          6,875     
'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Corgenix to Exhibit AspirinWorks(R) Test at ACC.09
2. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. Corgenix Signs Collaboration With Battelle
5. Corgenix Receives Two Additional Patents on AtherOx(R) Technology
6. Corgenix to Host Conference Call to Discuss First Quarter Results
7. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
8. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
9. Corgenix Reports Fiscal 2008 Financial Results
10. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
11. Corgenix Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... Oncothyreon Inc. (NASDAQ: ONTY ) today announced ... offerings of 10,000,000 shares of its Common Stock at ... for expected gross proceeds of $20 million and 10,000 ... a price to the public of $2,000.00 per share, ... of Series A Convertible Preferred Stock is non-voting and ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
(Date:9/18/2014)... a research lab can be pretty expensive. Now a ... has published an open-source library of designs that will ... piece of equipment: the syringe pump. , Syringe pumps ... for drug delivery or mixing chemicals in a reaction. ... dollars. , Joshua Pearce and his team of Michigan ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Doing science just got cheaper -- and faster 2
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
(Date:9/18/2014)... world-leading provider of scientific, technical and medical information ... Society (ARMS), recognized the academic research achievements of ... Researcher of the Year Awards. , The award ... Centre and in conjunction with the ARMS 2014 ... and New Zealand,s scientific community. Guest of honour ...
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2
... It may be news to its bankers, but Charlotte, the biggest ... financial industry, is actually an old growth forest. At least ... Charlotte is famous for having two kinds of green. It is ... residential neighborhoods and near-suburbs are also known for their lush yards ...
... Health Research Charity --Presents 2007 Prizes ,for Outstanding Psychiatric ... Prize winners have significantly contributed to the ... mental disorders NEW YORK, N.Y., Oct. 16, 2007Five ... be presented to scientists of great achievement by NARSAD, ...
... German . , Mammography continues to be ... breast cancer. However, because this technique is not as ... not deliver reliable results for every level of tissue ... works with rays of near-infrared (NIR) light instead of ...
Cached Biology News:Ecologists discover city is 'uber-forest' for big owls 2Ecologists discover city is 'uber-forest' for big owls 3Ecologists discover city is 'uber-forest' for big owls 4Ecologists discover city is 'uber-forest' for big owls 5Ecologists discover city is 'uber-forest' for big owls 6NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 2NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 3NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 4NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 5Contrast agent trials in swine 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide ... INERT GAS. A potent inhibitor of MMP-2 ... i = 1.7 μM). Purity: ... or DMSO. Unstable in solution, reconstitute just ...
MAb to Vasopressin Preservative: NaN3...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Biology Products: